ῌ,**/ The Japanese Society for AIDS Research +2 The Journal of AIDS ResearchHIVῌAIDS  
Japanese Contribution to the Development of an HIV/AIDS Vaccine
 :     : Gary J. Nabel National Institute of Allergy and Infectious Diseases,
National Institute of Health, USA







    1 : 2-῍3, ,**/

HIVῌAIDS 



!"#$%&'( )*+,#-.(/!"0#1$2(
34 5%6

R'>I& 03i98789:J;K?
&DNA 789:ST 30ai80[N789:?O2,T3K|bNO789:

# HIV 789:*,;.<=*,U 03- ?Hr(34 %VW#>&'(?& "@A)BC*-?'DX?&

YKZ

KZ[J\]g;

'( Global HIV Vaccine Enterprise +,-,;Gag ? Env i9¡ONK789:# 8.  <.=#> HIV E/0FG1& 789

A, B, C ai^_WX`¢£#034 5 Env:*?2HIJ*KLMNOP3*-QRS^_BC Env ¤a¥b Z¥b 30034

cBMKBCN?& 034

5TU%6$?#V' HIV 789:* DNA 789:?& i98789:

IWX'UY>3" NIH 789:*Z:[N#deG¦¦r( K|bNOfgKh'V

4\'(03 HIV 789:*5(R#5]$,2(ss34 %§i¨s?& j©kl&0?,&  5^:_`ab)],*c#-3TU,

ai8[N,20+NO789:*de67,f0& Gary J. Nabel 89:g;?

 2', HIV  Gag ? Env WX`¢£ª DNA

S+4

K|«20 m'(3 VLP virus-like particles 

3"789:*Z:[NhiNK HIV <\?
&+ jkj=I789:*2H>?&

7?%ZK,s0.

$h'V,&  N

[Ng;Kn¬2(34789:*BClE?& =#> mLn

 HIV 789:*op*qMi­

OKLo8^p:l;qr?s &0[KBC

r,T3789:)]s®tu?& 03 #de

8?0D34 @t HIV 789:A2HuvBG¦¯RPRPvg,S 034

CV'wDxy,z{35?E&05?V' &K^:_`ab#jwZV'°mZ,x3789|}~N,D3Y>mLnOKLo8^p:

:*,E/&+Zy¯h'V,&' zl;FD uv)]s.35?,T&,%Y20+Z789:g;K±#Tj,* &TU?P3G=?HD342(ss3Z:oai 78^² DIs ai
03 HIV 78

8[N 2', BCG {³´20+µK8[N79:J;KL,)]#Mi98

89:2%,s0 789:*|&}R

789:*, %N#789:)]?MD'Q& ~>4

 789:*Z:[N>I&K 7K2',5(R#*22( 03789:?
O2g;KPV'Q2(3Y-$?& ?'D'
(3+, , 4
./6 :  ¸+0,῍20.* {³¹º» +῍,-῍+"-=BC8¨BChiNK
Fax : *-῍/,2/῍++2,**/  . ¼ ,1 + !"#$%&'( HIV-+ )*+,-!"
./Control of HIV-+-speciﬁc acquired/adaptive immunity by modulation of innate immunity  ¶<7qZ·2-,-

H Takahashi et al : Japanese Contribution to the Development of an HIV/AIDS Vaccine

Hidemi Takahashi Department of Microbiology and Immunology, Nippon Medical School

 

 !"# $%& '() T  CTL : cytotoxic T lym*+

phocytes,-. /CTL  012-  34567
*8(ῌMHC 9::;<2-=9>% ?9@

Apopto-sis ABCῌD%  !"#.

/E% CTL# CTL FGH I

ῌ +


FGH

ῌ ,

Poly I : CJ B1 K LMN9 O%PQ* 

34567

>RST)4

 CTLPQ

poly I : C A

U

V 8(ῌMHC 9::;<#/:*W 
. :/X* 8(ῌMHC 9Y,;<2-345
67  012-Z  :[\,-] PQ Z*^2/:* CTL

 _ . /E%_ P

Q#/:*`ab#&*c/defgh

CTL

ij#k

l]

mn:].
o,/-p    Z PY,qr%stfu vwx% ISCOM :`Eyz{|uT::}~%:/X RST)43456&8( ῌ MHC G

# CTL *:  %



I

/

2-/

PQ*J/:0

%]. %   Z9
 %PQ* Ru6)h %8(῍MHC 9A;<#  

8(ῌMHC 9 #/:1, 2

MNQA

CTL



%

PQ

# poly I : C A O
%MN2-= cross-presentation * CTL *

2- gp+,* ZPQ
RST)43456

2-

7H2-

8( ῌMHC 9::

 CTL *2-/: %  -3.  gp+,* Z rPQ  ¡ #"¢  LPS#` TLR

%MN%= £¤8(ῌMHC 9># CTLI : C KA TLR-

&  CTL

*

,-



%MN2-= 

 #/:*',Y:. / ()*2-Y, + *¦k ª%« +¬/:*­ ®)4A2-+*.
p o,?9¯ Gene Gun A°±p-²³6 gp+,* Z# CpG µ5)¶}~%:/X;<2-

RST)43456& % PQ* ¨© # poly

6 DNA

 ,. 

% poly I := D&§%Z gp+,* Z

2.

HA Z

C ::}~%= HA Z 345

;<%`/:* 2-  , poly I : C ::.

UV*PQ% ^#/: ``Y:[\ij .  !%  Influenza . ¦k /:Y, &  CTL   c2- RST)4&<%].

Ru)4Z gp+,*

dsRNA

 CTL

,-Y. 2, HIV-+ :$ :%6RST)4 & *      ^      O #  :   2 - % TLR-%;<c2-¥ p&%;<# cross-presentation/E%v]  + <%AE HIV-+

2- Cross-presentation³)6#4(´}~#= / ²³6 TLR1
%4(´6 DNA³)¹ºu®#/:A&MN
·¸ CTL *2-/:  %`++.
¦k Z
TLR-#`»85u¼`

%  % PQ MNῌFG

The Journal of AIDS Research Vol. 1

No. ,

,**/

W
Masafumi Takiguchi KDivision of Viral Immunology, Center
for AIDS Research, Kumamoto UniversityW
HIV-+ 4XY ; Z[ \Z["#E]^ #[_` a7 HIV-+ 
b"#%c ^#[_def( NOY"g$ ((N OYhijkl m#=&

4Xno(%pp ,/῍-* hi(=EY(%kEm#=$ ((qcPQ%"#=E]^ [_%r HIV bs%

p  k HIV tuv,wxTs y%6=%$HIV-+ 4Xj7l FG#=$ z{|} Sex worker ~ HIV-+ ῌ

(=

E]^ HIV-+ 4X(%k
m#= #k%r4X(%`c6=%$ HIV-+ ; ;4Xs(= CD. }ST  CXCR.
#4X">Z,R

 CCR/ ! k~  CCR/  -,(= CCR/-, #$6=km#=$  CCR/-, %&'k0l(kqzzk=%$ $

HIV-+ 4X(==E )oppY(%k KY : long-term non-progressorW Y
k Kslow progressorW m#=$ #k~ CCR/-, *$6-

Poly KI : CW¼gp+,* /0` B


CTL

=km#=$ p HLA z|TNOY HLA-B-/ NOY $ HLA-B/1 B/+ B,1 N O
Y ¡ %6$

 TLR1 

& '()*+,-./0(!"#$ %

HIV-+

+

B

CD2T ;"# HIV-+ £HIV-+ tu.U(=FG#$ ª >?

 CTL 12345"#%6 7,¥` 8"#9:; <(=>?@ A"#0«( #`

tu®'` B

CTL CDEFG#$ HLA *¢ῌ`+¤,¥( ¦-§¨©TCR / perforin  granzyme
HIV-+ 4X;

¬­(= HIV-+a7 HIV-+ tu.

U(`'E $ E'§ TCR 
/ HIV-+

B

CD2T ;

¯

w}

,°a

( #¯ w} ,`6= HIV-+ ; ±²

, HIV-+  CTL  HIV-+ 
Epitope-dependent e#ect of Nef-mediated HLAclass I down-regulation on ability of HIV-+speciﬁc CTLs to suppress HIV-+ replication/³´(

HIV-+ µ7tu.UE$ ¶

MIP-+  RANTES `'%} ,

HI J KLMN OMPQR,STY HIV-+ ¹ CTL ºZ»"UVn IFN-g %3 $ ¦#-§¨©`HIV-+ tu.U"#FG#$ ·¸

2/K ,/ W

H Takahashi et al : Japanese Contribution to the Development of an HIV/AIDS Vaccine῏ HIV  HIV  CTL  !

5789: HIV-+ 
N HLA ῌ78%& HIV-"# $%& '()* SIV +,& CD2T -./0%+ ZC& 8% CTL  {/ HIV-123 456789: 88+ ,GH7\]^_`:& CTL  HIV-+ ;<῍=>?@A/B(C8,D+$:j  ,& b HLA-B-/*+  CTL& HLAE+,& FC HIV-+ , CTL GHIJ+

ῌ-.#+5/¡8`¢ Nef /£N( HIV-+ hNL-M,*Al C( CD$+$K: '(& $L HLA /MN(O.T -.vC-.¤¥/Z7& Nef pq¦§& 3 456PQC(%RSC(%7O(T¨J7 HIV-+ hNL.-,l C( CD.T -.vC

UK: 8VWXY/Z[7\]^_`-.¤¥/Z`8/DC(: `&(: Eab,& HIV c& ?d!efg h+ ij

8 CTL

#,& ©+$ NL.-, ;<kl 3 4/56C(mn"# +$: 8mn+/῍=C& ) ty /ª«78& NL.-, ,& C7o Env pqVr(N(ab3st#-./ {C8/DC(+,l: a& 3 4

uvCw CTL x(: CCῌ + yzc

56PQ¬­7 HLA +$ HLA-B*/+*+ Z783st#ur CTL ®b HIV-+ 3st#u& ¬­C HLA-A*--*- |/MN(}*{+?2NC'

~7& CTL /Z7b3st#uv7 CTL

#& NLG8+?(!} * ,;<C& mn.-, ;<῍=J NL.-,  CD.T -.v7-.

 /CC'N(+$: 8& 3s¤¥/¯(: E°B& 3 456PQ¬­7

t#ur|%& CTL 

HLA +$ HLA-B*/+*+ Z7b3st#u/{ HIV-+ GH7

IJY: a Nef pqC({7 CTL ,& Nef  HLA

HIV-+ C(-.+,& HLAI 5,{J±²/³´µ& NL.-, ;</w2῍=C-.M|d& Nef pq

78 h¶ . Al& HIV-+  CD.T -./·῎¤¥C HIV-+ C(-.+, HLA

78/DC( h¶ . Bl: 8 CTL ,&



 ῌ



I 

ῌ . Pol & HLA-B*/+*+  CTL -.¸¥} * ;<῍=A¹ b Pol  HLA-B*/+*+  CTL , NL-.-, ;</w2῍=C(: a& º CTL ,»;<῍=J¼2;<῍=J/Z`N(:
B¹ b Pol & HLA-B*/+*+  CTL ,& NL-.-,  CD.T -.vCw-.¤¥
/ZC(: a& º CTL ,& -.¤¥/Z`N(:20

h ,0 lThe Journal of AIDS Research Vol. 1

HIV-+  HIV-+ 

+-  HLA-B*/+*+  

No. ,

,**/

DC  ,)-N;+1 "

- HIV-+ %STU&VBC(, - ! long-term non-progressor  "#

01 DC <)5|01",)=>+ ~Pol $%&'

?32D HAART .`1 HIV-+ @5

CD2T ( )* +",- HIV-+ ./01,

y, CD. T ( xA~ r HIV-+ .C- 

Protective immune response against HIV-+ in the
hu-PBL-SCID mice induced by intra-splenic immunization with inactivated HIV-+-pulsed dendritic cells 2 345567589:;5

B;

;DAZE0",- , 3> DC {5|A0 )D " HIV-+ a;{^ DC ;32)F ,
DC  )ῌb*(3PBMC *4

GM-CSF , IL-. ,-",.N[,-] "12G9 DC BCMNOP.H "IJZ[ HIV-+ .KL0 /. I

Yuetsu Tanaka 3Department of Immunology, Graduate

W . ,01 IFN-beta

School and Faculty of Medicine, University of the Ryukyus

lN ;( X£sun¤ 1<=(

3dendritic cells : DC , > ;?[0 DC ;.N/X£ PBMC - HIV-.0@A BC ( D DC EF

+ .C

,01



GHI J !."0 K-L

#0$C

MNOP ;? QR %STU&VWX'  Y01BC'T(

Z [+\

+\ <=( (])^_`1a)ῌb*

+.

T(

;?)+",3§ /

STU4) CCR/ª

 HIV-+ .C01Qv

fM0 Y [,

D «;$¬­®¯BC

+ HIV-+ ?

)gh+\> +D #_N Qv ;?)+

4Jcd( - DC +e (
T(

¥¦0

O¨.©P8¥ " DC ;su

-0 .

,

¡1 , M¢,- DC ;.N°.

CD. T () HIV-+ BC. /ia.0 12 DC ;32,jk l

.R?01±² ³´D, "mnopq.r1 DC ( ;32 HIV-+ st³´;subµ.S  ;su-Gquv.4wD",) + CD. T (HIV-+ 

DC xyz,{5|)6}+

1 #_N 7 DC  CD2- 8~)^", 39 ) r SIV-+ q: STU /CD2 T (HIV-+ ¸ ,¶n· BC (CD. T ( ¦¹)º¯»o¼tT,'³´ ±² "³´ 3CD. ³´ 

X. HIV-+ .TwD

Immunization of hu-PBL-SCID against HIV-+21

3 ,1 

H Takahashi et al : Japanese Contribution to the Development of an HIV/AIDS Vaccine  +*  Da




 

 



HIV-+





.ῌ

  !"# CD. "

CTL ῍ HIV ῒῑΐῐ῏῎CTL-based control of SIV replication

$%& '(  ) *+,-./

pq rs tuuM~0 T  1 ( CD. " 2 CD. / CCR/ 

Tetsuro Matano Graduate School of Medicine, The Univer-3

sity of Tokyo

4%  5&5 0 PBMC

16 R/

HIV-+

78 9:;<DNA =>=



)4% :! ?

" CCR/ @ CD.

Ohd 2(L;<)z{'%K |g}7

R/ HIV-+ 7D EFGA)_0 ?@)V9 u'E~# yd6OM

A3B!C
 

! ?@

 H*

R/ HIV-+

+,-./"IJ#) $ HJ#

HIV 7v 1 ( 7c FGwxyd6`+-@5(  T iI CTL
) HIV ,A(?@)%K % *;<*+,-.LJ# ( ) HIV 7  1 ( CTL )FG

9: CD. "%&H

"IM

3 ?@)'(' 3) ?



NE

CD. "A*+,-. C /0 1A2(  3845' 6O*;<&%7%! CD.P T AL

HTLV-I Q<+R-S-TU ?@ 2 8

9"A-.
: ;W

 CD.P T C)7%( V

HIV-+ XYZ[\A !<]^=>_?

L&&%K HIV D

%K|g}7

)_0  5!)( HIV ) CTL

2 DA$  (DN#W ? N6( ¡[FG CTL

2 HIV  D lKA}V5(  ?: 
CTL FG¢¡[@5( DNA ZQ£ῌ¤¥;< SeV ¦--<T<§£A5  

2 ? "A-.  CD.P T  6O HIV-+ ! CTL FGKA

X ;W `a-ZA@A ?@A%& 5! b¨`©h 16;< DFG12g`

c CD2P T  6OdB 9 (L%& 5(eE©vFGA%& 5('!+/ V: ? CD)#) DC )f- T 12gShi- T &¨`©h@ª5( SIV A !|`%

j1 HIV-+ Ek, CTL dBAFG

?@&%L DC 6OH?) HIV-+ 7AIHῌJAlK

@mn%
3)
AQ

@@@L  SHIV23.0P 7©h |g}7AE~@

H HIV 7v

A2h« h@mn%( )   D
2#?@)%(+0 W

SIVmacDC 6OH?oL p'MNO P DC,-3 [¬­.] DNA ZQ£ ῌGag 3 SeV

Rῌqr&%45¦--<¡[; 2  v® /  1

 :! tu6 S

:?As0?@#

DC At 2vwxyzt? {T |UN D,6OdB)FG& 9(L}V)CD# *;< ~#) iW {X5!*;< DC( SIV  D)@%! ?% CTL FG¡[; 2(@ ?

SIV  D#)

! ?

/  v® #xDy¯X MHC

YZ[E *;< h°ZZ 3*-+,*-a A±  -  SIV [¬ 1 \w@](  X75! DC FG­.c + ²@ v+ 8  #± ;

!Ek, CTL ) DC A &%# 9:<³£k)?@)%&@! ? 

#^
)`a

6OdB)_05!c E#bc DCd

XEk, CTL

6Oef#k SIV Gag v :! HIV-+ A=), g(  T  DC @,+0 Ek, CTL

hd>_?@0+1

2;<A-.



DC 6OIHi8  HARRT @ -TU,+0  T&%¤i´ µ¶³ · Gag,+0S

? ?

¸g9EL  Gag,*0-`<¹-Zk#! ¡

SIV  D $A ?@A,)CD&L5  %  0_j5! DC A

@5( Gag,+0S k?@ IL-+* -./ D T FGAzk ?@ :K Gag,+0S kA  SIV - DNA A_! DC 6OlKlE

5 ?A ( Gag,+0S k SIV A_5! Rῌ

HIV-+ X`a-Z

%¢Aº! :dB  T @ B AFG !  DC 'q"»I´ 7£¤] (;<­¦A¥pl;m!@? Gag,+0S k SIV lK#) 

HIV-+ XA7

v?@)no,#Kq.¢ SIV @ª5(¦¼5(?@)%&@! %  Gag,*0-,+0 Ek, CTL -§22

 ,2 

The Journal of AIDS Research Vol. 1% 0

 Gag,*0-,+0



,**/

CTL gh+-1()I SIVmac,-3  B

  SIV  

No. , SIV  

CTL  Gag,+0S

 SIV  !
" MHC #$%&'$ 3*-+,*-a () , /

DIs  !"#$
Vaccinia DIs based HIV vaccine controls challenge virus infection   SIV *+%,- DNA  G,+0S

 SIV

O P Td/0YZ1E'YZe-&,

*+%,- DNA ./01

! 2

Kenji Someya TAIDS Research Center, National Institute of3')4 RNA 5 16 + 7ῌ 89:; , 7

Infectious Diseases

)QRST+-U+ 3'

 SIV  < =6  SIV ;> ?

)4.V I  TDIE!

t DIs +2  3')4\[\@A< SIV  BCD()  CTL E4F,$ + JW;XVYZ*] C +/.. kbp  DNA ^<G!"H_`a TCEF > bc7a> dDIJ KL Gag,*0-,+0

CTL M! HIV  !"N#$O? =C% SIV  G&'

89 e+-=fgh Di%CD< ) DIs  %+-i+&,P(< MQ

CTL  SIV 



O

BRS%J !

4%  +3! WX{ DIs ^] j\* hkl¡¢£m ¤/ HIV ¥c SIV \*l¦§h¨©-ª«-¬i+&, TrDIs

t! )YZ rDIs 3')4

8 \-].^.^_`^aYZbMcd/0^  f^% dD8 DNA +

YZ1- ¨©-ª«-¬ BCG +- TrBCG ©-ªT)U*VWXYZ +?XB[,H8J!

 ()  d/0YZ1 ῌ 23`^4567e-&,ῌ89f[g:XB[,h! A
SeV i+&,j;ῌkl mn<=> o?p­,}®-+-fgh@n¯,*!
SIV gag ῌ pol \*l¦§h rDIs

4 in vitrofYZ1q ῌ r@A> od/0YZ1q Mc3')4%¥c SIV Gag ;°o5 rDIs

DNAVEC s:X CTL +%,-tB

p CEF ±%  bc7a

CuvD> ow).^q  () MHC 5

BHK-,+ CV-+ RK+- a>  SIV

EFG> o-]`bxb.^q ῌyHIz> o{|

Gag &-²+ CEF .^q ῌ J)KLYZ1 ῌ J)E4E)},s:°¤>! rDIs f³% ¥ci%

D bc7a8;

XB[,h! MM<~h?"N¤´34µ¶) 4 f³%n¯·³ 

J!

IFN-g ELISPOT q i%rs¸¹º»

23t¼

T ,3 

H Takahashi et al : Japanese Contribution to the Development of an HIV/AIDS Vaccine SIV gagῌpol rDIs  MVA  rMVA

BalbῌC!

5 / #% ()*# SIV gagῌpol^;w

xM~!y="z{ XHGbc;"# + $% &' , $()% ()* , +,# SIV Gag -wxM!y="HG45qr7./ IFN-g 0123  4567% rDIs ' rMVA

DNA ~PQ% rDIs PQ#8mly ῌ#89:;<=5()>?@ABC;DE@FGH

"PQ@wJqr7 o^DE@FGH#C#C Scid

67%!" IJKLM5NO'% rDIs   1 A v=tu= IJNO'% SIV DNA PPQ !"#'.RSTUVWXY5Z['\Q% yῌ"PQ% rDIs PQ% ]^;DE@CSH_ `a% rMVA PQ

= DNAῌ = DIs PQ5 . #% ()!"'TUVW'\]bcSH_@% `dM5XYZ*#wxM SHIV z{l!y=" RNA E[@]eGc DcG567HG% rDIs ' rMVA Ef

CD. M235HGqr7g5()hM

S!y=" RNA E CD. M23567

ijS@G% KLM#kl' rMVA #8mlnJDE@opbc
rDIs 5qr()s' /HG% v=tu=#Jli !"tu=f# DNA ~!"tu=v=tu=

J% wxM!y="5z{|}NO BalbῌCI!"

SIV DNA ~ - $PQ% SIVDNAῌrDIs PQ

PQ% rDIs PQ#8mlyῌ"P
Q@wJqr7
B v=tu=o^DE@FGH#C  1

IJ rBCG E rDIs 5

yῌ"%  = DIs % SIV DNA

~5 SIV Gag -./()>?567'%/ $PQ%  = DNAῌ = DIs PQ

rBCG, rDIs ()#8m% rBCGῌrDIs ()'wJ

ῌ 1

3*

 -* SIV DNAῌrDIs ~5qr()7

The Journal of AIDS Research Vol. 1

SIV Gag T 

No. ,

,**/

 

munogenicity of human immunodeﬁciency virus particles rDIs  ! "#$and corresponding polypeptides in a DNA vaccine. J%&'$()*+,-./01234567*89:;

Virol 13 : 0,0ῌ0-+, ,**/.
/ L Takahashi H, Takeshita T, Morein B, Putney S, Germain:+<= BCG #$%&'$()* BCGTokyo+1. >?@A HIV BCDE῎FG

HIJ*K1,+L '$()?@A89:;

7;M

RN, Berzofsky JA : Induction of CD2» cytotoxic T cells
by immunization with puriﬁed HIV-+ envelope protein in
ISCOMs. Nature -.. : 21-ῌ21/, +33*.

NO5P QRSTUFG 4

0 L Takahashi H, Nakagawa Y, Yokomuro K, Berzofsky 4WKFQRX6YῌZ

JA : Induction of CD2» cytotoxic T lymphocytes by

VJ:;,,L[\]A51 BCG ^G_NO`:;
7ab
*

,-L

 cd&ef_Fgh*ij89:; ^G_kSAl

immunization with syngeneic irradiated HIV-+ envelope

67

mn

derived peptide-pulsed dendritic cells. Int Immunol / :2.3ῌ2/1, +33-.

rBCGῌ rDIs #$%&4 :opK#$

1 L Nakagawa Y, Takeshita T, Berzofsky JA, Takahashi H :%&'$()*c&qr)st&06#$%&4F

Analysis of the mechanism for extracellular processing inHI uvw56

the presentation of human immunodeﬁciency virus-+ en-῍ ῌ ῎velopeHIV #$%&xyWKz{|}~)P

WK 4WK#$%&/;
6  ,* z$῍gP

6

#$%&4d@ub  #$%&

peptidetoepitope-speciﬁc,***.
2 L Takahashi H : Antigen presentation in vaccine development. Comp Immunol, Microbiol & Infect Dis ,0 : -*3ῌ-,2, ,**-.

6 HIV #$%& HIV DE

3 L Fujimoto C, Nakagawa Y, Ohara K, Takahashi H :)(῏ ¡R¢#$%&:

Polyriboinosinic polyribocytidylic acid [Poly (I : C)]/; £¤¥¦1§¨©01 Phase III g

TLR- signaling allows class I processing of exogenous

01ªA¡R¢A¡R¢s«

protein and induction of HIV-speciﬁc CD2» CTLs. Int;

protein-derived

cytotoxic T lymphocytes. Immunology +*+ : 10ῌ2,,

6  4WK HIV #$%&¬ A,Ku ªAFQR 6#$%
&­G56*89:;

Immunol +0 : //ῌ0-, ,**..
+*L Schultz O, Diebold SS, Chen M, Naslund TI, Nolte MA,®¯y©0hAlexopoulou L, Azuma YT, Flavell RA, Liljestrom P,

°±WK²³ ´®µ¶¬; 6

Reis e Sousa C : Toll-like receptor - promotes cross-7·F¸^G_²³

priming to virus-infected cells. Nature .-- : 221ῌ23,,¬¹º:;6,**/.
++L Hidaka C, Norose Y, Nakagawa Y, Shimizu M, Ohwakiῐ῏+ L Nabel GJ : HIV vaccine strategies. Vaccine ,* : +3./ῌ
+3.1, ,**,.
, L Nabel GJ : Challenges and opportunities for development of an AIDS vaccine. Nature .+* : +**,ῌ+**1,,**+.

A, Nohtomi K, Toda M, Kusagawa S, Sakaguchi M,
Kudo S, Takebe Y, Takahashi H : Dermal dendritic cells
sensitized with plasmid DNA encoding immunostimulatory sequence by gene gun e$ciently prime murine
HIV-+-speciﬁc CD2» cytotoxic T lymphocytes. Biomed
Res ,/ : 2-ῌ3+, ,**..
+,L Tomiyama H, Akari H, Adachi A, Takiguchi M : Di#er-- L Seaman MS, Xu L, Beaudry K, Martin KL, Beddall

ent e#ects of Nef-mediated HLA class I down-regulation

MH, Miura A, Sambor A, Chakrabarti BK, Huang Y,

on HIV-+-speciﬁc CD2» T cell cytolytic activity andBailer R, Koup RA, Mascola JR, Nabel GJ, Letvin NL :cytokine production. J Virol 10 : 1/-/ῌ1/.-, ,**,.

Multiclade human immunodeﬁciency virus type + enve-+-L Tomiyama H, Fujiwara M, Oka S, Takiguchi M : Cut-lope immunogens elicit broadcellular and humoral immu-

ting Edge : Epitope-dependent e#ect of Nef-mediatednity in rhesus monkeys. J Virol 13 : ,3/0ῌ,30-, ,**/.

HLA class I down-regulation on ability of HIV-+-speciﬁc. L Akahata W, Yang ZY, Nabel GJ : Comparative im-

CTLs to suppress HIV-+ replication, J Immunol +1. :3+¼ -+ LH Takahashi et al : Japanese Contribution to the Development of an HIV/AIDS Vaccine-0ῌ.*, ,**/.
+.῍ Yoshida A, Tanaka R, Murakami M, Takahashi T,tion as a new replication-deﬁcient viral vector. Virology-*, : .--ῌ..., ,**,.

Koyanagi Y, Nakamura M, Ito M, Yamamoto N,,*῍ Someya K, Xin KQ, Matsuo K, Okuda K, Yamamoto N,

Tanaka Y : Induction of protective immune responses

Honda M : A consecutive prime-boost vaccination ofagainst R/ HIV-+ infection in the hu-PBL-SCID mice by

mice with simian immunodeﬁciency virus (SHIV) gag/

intra-splenic immunization with HIV-+-pulsed dendritic

pol DNA and recombinant vaccinia virus strain DIs

cells : possible involvement of a novel factor of humanelicits anti-SIV immunity. J Virol 12 : 32.,ῌ32/-, ,**..

CD.῎ T cell origin. J Virol 11 : 21+3ῌ21,2, ,**-.

,+῍ Hesseling AC, Schaaf HS, Hanekom WA, Beyers N,+/῍ Matano T, Kano M, Nakamura H, Takeda A, Nagai Y :Cotton MF, Gie RP, Marais BJ, van Helden P, Warren

Rapid appearance of secondary immune responses andRM : Danish bacille Calmette-Guerin vaccine-induced

protection from acute CD. depletion after a highly

disease in human immunodeﬁciency virus-infected chil-pathogenic immunodeﬁciency virus challenge in macaques vaccinated with a DNA prime/Sendai virus

dren. Clin Infect Dis -1 : +,,0ῌ+,--, ,**-.
,,῍ Someya K, Cecilia D, Nakasone T, Ami Y, Matsuo K,

vector boost regimen. J Virol 1/ : ++23+ῌ++230, ,**+.

Burda S, Yamamoto H, Yoshino N, Kaizu M, Ando S,+0῍ Feinberg MB, Moore JP : AIDS vaccine models : chal-

Zolla-Pazner S, Okuda K, Yamazaki S, Yamamoto N,

lenging challenge viruses. Nat Med 2 : ,*1ῌ,+*, ,**,.

Honda M : Vaccination of rhesus macaques with re-+1῍ Matano T, Kobayashi M, Igarashi H, Takeda A,

combinant Mycobacterium bovis bacillus Calmette-

Nakamura H, Kano M, Sugimoto C, Mori K, Iida A,

Guérin (BCG)-Env V- elicits neutralizing antibody-

Hirata T, Hasegawa M, Yuasa T, Miyazawa M,

mediated protection against simian-human immuno-

Takahashi Y, Yasunami M, Kimura A, O’Connor DH,

deﬁciency virus with a homologous but not a heter-

Watkins DI, Nagai Y : Cytotoxic T lymphocyte-based

ologous V- motif. J Virol 13 : +./,ῌ+.0,, ,**/.

control of simian immunodeﬁciency virus replication in a,-῍ Kanekiyo M, Matsuo K, Hamatake M, Hamano T, Ohsu

preclinical AIDS vaccine trial. J Exp Med +33 : +1*3ῌ

T, Matsumoto S, Yamada T, Yamazaki S, Hasegawa A,+1+2, ,**..

Yamamoto N, Honda M : Mycobacterial codon opti-+2῍ Tagaya I, Kitamura T, Sano Y : A new mutant of

mization enhances antigen expression and virus-speciﬁcdermovaccinia virus. Nature +3, : -2+ῌ-2,, +30+.

immune responses in recombinant bacille Calmette-+3῍ Ishii K, Ueda Y, Matsuo K, Matsuura Y, Kitamura T,

Guérin expressing the human immunodeﬁciency virus

Kato K, Izumi Y, Someya K, Ohsu T, Honda M :Structure analysis of vaccinia virus DIs strain : applica-3,ῌ -, ῍type +Gag. J Virol 13 : 21+0ῌ21,-, ,**/.